KMS88009 is a potent small-molecule agent that directly interferes with the formation of amyloid-β oligomers, thereby preserving cognitive function when used prophylactically and reversing cognitive decline when used therapeutically; it significantly reduces amyloid-β oligomer assembly and improves cognitive behavior in APP/PS1 double-transgenic mouse models of Alzheimer’s disease upon oral administration both before and after symptom onset, demonstrating its potential as a powerful therapeutic candidate for Alzheimer’s disease.